Skip to main content

Table 1 Patient characteristics from study 1 and 2

From: Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy

Clinical data

Total

n = 79 (%)

Study 1

N = 30 (%)

Study 2

n = 49 (%)

Gender

 Men

64 (81%)

22 (73%)

42 (86%)

 

 Women

15 (19%)

8 (27%)

7 (14%)

Median age, yrs. (range)

68 (35–82)

68 (35–82)

68 (48–80)

Stage

 Locally advanced

26 (33%)

13 (43%)

13 (27%)

 

 Metastatic

53 (67%)

17 (57%)

36 (73%)

Treatmenta

 Cisplatin + gemcitabine

46 (59%)

22 (76%)

24 (49%)

 

 Carboplatin + gemcitabine

9 (11%)

6 (21%)

3 (6%)

 

 Vinflunine

3 (4%)

1 (3%)

2 (4%)

 

 Pembrolizumab

20 (26%)

0 (0%)

20 (41%)

Admission to hospital

 No

32 (41%)

10 (34%)

22 (45%)

 

 Yes

46 (59%)

19 (66%)

27 (55%)

  1. aOne patient in study 1 never started treatment due to cerebral stroke before initiation of treatment